BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis

被引：34
|
作者：
Schultheis, B [1 ]
Wang, L
Clark, RE
Melo, JV
机构：
[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Haematol, London, England
[2] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England
来源：
LEUKEMIA | 2003年 / 17卷 / 10期
关键词：
D O I：
10.1038/sj.leu.2403079
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2054 / 2055
页数：3
相关论文
共 50 条
  • [21] Nilotinib and allogeneic stem cell transplantation in a chronic myeloid leukemia patient with e6a2 and e1a2 BCR-ABL transcripts
    Langabeer, Stephen E.
    Crampe, Mireille
    Kelly, Johanna
    Fadalla, Kamal
    Connaghan, Gerard
    Conneally, Eibhlin
    LEUKEMIA RESEARCH, 2010, 34 (08) : E204 - E205
  • [22] BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients
    M Marega
    R G Piazza
    A Pirola
    S Redaelli
    A Mogavero
    I Iacobucci
    I Meneghetti
    M Parma
    E M Pogliani
    C Gambacorti-Passerini
    Leukemia, 2010, 24 : 1445 - 1449
  • [23] BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients
    Marega, M.
    Piazza, R. G.
    Pirola, A.
    Redaelli, S.
    Mogavero, A.
    Iacobucci, I.
    Meneghetti, I.
    Parma, M.
    Pogliani, E. M.
    Gambacorti-Passerini, C.
    LEUKEMIA, 2010, 24 (08) : 1445 - 1449
  • [24] BCR-ABL FUSION TRANSCRIPTS' FREQUENCIES IN SUDANESE CML PATIENTS
    Muddathir, AbdelRahim
    Kordofani, Anwar
    Fadl-Elmula, Imad
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2014, 36 : 57 - 57
  • [25] Chronic Myelogenous Leukemia with the e6a2 BCR-ABL and Lacking Imatinib Response: Presentation of Two Cases
    Vefring, Hege K.
    Gruber, Franz X. E.
    Wee, Line
    Hovland, Randi
    Hjorth-Hansen, Henrik
    Dahl, Tobias Gedde
    Meyer, Peter
    ACTA HAEMATOLOGICA, 2009, 122 (01) : 11 - 16
  • [26] Chronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: Transformation to lymphoid blast crisis
    Martinez-Serra J.
    del Campo R.
    Gutierrez A.
    Antich J.L.
    Ginard M.
    Durán M.A.
    Bento L.
    Ros T.
    Amat J.C.
    Vidal C.
    Iglesias J.F.
    Orlinska I.
    Besalduch J.
    Biomarker Research, 2 (1)
  • [27] Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia
    Phan, Chin-Lee
    Baharuddin, Puteri J. N. B. Megat
    Chin, Lai-Peng
    Zakaria, Zubaidah
    Yegappan, Subramanian
    Sathar, Jameela
    Tan, Sen-Mui
    Purushothaman, Visalachy
    Chang, Kian-Meng
    CANCER GENETICS AND CYTOGENETICS, 2008, 180 (01) : 60 - 64
  • [28] Allosteric Bcr-Abl Inhibitor ABL001 Overcomes Bcr-Abl Tyrosine Kinase Inhibitor Resistance and Enhances MDM2 Inhibitor CGM097 Activity in Blast Crisis CML Cells
    Tao, Wenjing
    Mak, Po Yee
    Andreeff, Michael
    Carter, Bing Z.
    BLOOD, 2017, 130
  • [29] Secondary imatinib resistance presenting as blast crisis, related to an aberrant bcr-abl fusion gene.
    Janssen, JJWM
    Hochhaus, A
    van Oostveen, JW
    Schuurhuis, GJ
    Ossenkoppele, GJ
    BLOOD, 2003, 102 (11) : 319B - 319B
  • [30] CML with an e1a3 BCR-ABL fusion:: rare, benign, and a potential diagnostic pitfall
    Al-Ali, HK
    Leiblein, S
    Kovacs, I
    Hennig, E
    Niederwieser, D
    Deininger, MWN
    BLOOD, 2002, 100 (03) : 1092 - 1093
12345